Status:

COMPLETED

FibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy

Lead Sponsor:

Afdhal, Nezam, M.D.

Collaborating Sponsors:

Echosens

Conditions:

Cirrhosis

Hepatitis B

Eligibility:

All Genders

18-90 years

Phase:

NA

Brief Summary

This study will examine the effectiveness of the FibroScan device in differentiating fibrosis in patients with hepatitis B and C. The FibroScan measures liver stiffness and will be correlated to the l...

Detailed Description

STUDY OBJECTIVES: Co -Primary Aims: * Diagnosis of cirrhosis in patients with chronic viral hepatitis B and C; * Correlation of the FibroScan measurement with Metavir liver fibrosis scores by differ...

Eligibility Criteria

Inclusion

  • Subject is able to give informed consent for this study and agrees to provide a blood sample.
  • Subject must be at least 18 years of age.
  • Subject has had or will have a liver biopsy for chronic liver disease, secondary to HBV or HCV or within 6 months of FibroScan (experimental cohort 1 only).
  • Subjects who have hepatitis C (HCV) or hepatitis B (HBV) should be treatment naïve or off interferon therapy or nucleoside/nucleotide analogs for HBV for a minimum of 3 months prior to the FibroScan and liver biopsy.

Exclusion

  • Unable or unwilling to provide informed consent.
  • Confirmed diagnosis and/or history of malignancy, or other terminal disease.
  • Uninterpretable biopsy specimen.
  • Missing critical clinical, biochemical and/or demographic information.
  • Receiving anti-viral therapy for infection of HCV or HBV within 3 months prior to the FibroScan and liver biopsy.
  • Subject with other chronic liver disease, including Wilson's disease, alpha 1-antitrypsin deficiency, cholestatic liver disease, or hemochromatosis.
  • Patient with clinical ascites.
  • Patients with morbid obesity defined as a BMI of greater than or equal to 40.
  • Patients who are pregnant.
  • Patients who have an implantable cardiac device such as defibrillator or pacemaker.

Key Trial Info

Start Date :

March 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2008

Estimated Enrollment :

907 Patients enrolled

Trial Details

Trial ID

NCT00125762

Start Date

March 1 2005

End Date

October 1 2008

Last Update

October 27 2017

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

BIDMC

Boston, Massachusetts, United States, 02215

2

Bruce Bacon M.D.

St Louis, Missouri, United States

3

Duke University Medical Center

Durham, North Carolina, United States

FibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy | DecenTrialz